Company news
NeOnc Technologies Holdings, Inc. news in 2026
NeOnc Technologies Holdings, Inc.'s news releases, calls and decks from 2026, newest first.
NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
November 17, 2026
NeOnc CEO Amir Heshmatpour’s 2026 Open-Market Share Purchases Exceed $1.5 Million
November 16, 2026
Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO
November 13, 2026
NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
November 13, 2026
NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial
November 12, 2026
NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations
November 12, 2026
Brain Cancer Breakthrough Hopes, a $30 Million Robotics Deal and an AI Gold Rush
November 11, 2026
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
November 11, 2026
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
November 11, 2026
NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases
November 10, 2026
NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues
November 9, 2026
NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
November 5, 2026
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage
November 2, 2026
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
November 2, 2026
NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage
October 30, 2026
NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
October 26, 2026
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
October 23, 2026
NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight
October 22, 2026
NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy
October 22, 2026
NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches
October 21, 2026
NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward
October 21, 2026
NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration
October 21, 2026
Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season
October 20, 2026
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
October 16, 2026
NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
October 16, 2026
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
October 16, 2026
From Shaq to Musk: The Power Appointment Effect
October 15, 2026
UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances
October 15, 2026
NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026
October 15, 2026
NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development
October 14, 2026
NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors
October 14, 2026
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
October 7, 2026
NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt
October 6, 2026
NeOnc’s Powerful Brain Cancer Pipeline Advances
September 29, 2026
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
September 28, 2026
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
September 17, 2026
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
September 16, 2026
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors
September 9, 2026
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
August 13, 2026
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
August 12, 2026
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
August 11, 2026
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
August 10, 2026
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
August 10, 2026
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
July 27, 2026
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
July 15, 2026
NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum
June 23, 2026
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
June 23, 2026
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
June 22, 2026
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates
June 15, 2026
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
May 18, 2026
Calls in 2026
Decks in 2026
- Investor Presentation (November 2026)
Investor deck · 57 slides · Nov 18, 2026
- Investor Presentation (October 2026)
Investor deck · 57 slides · October 2026
- Corporate Update (August 2026)
Corporate update · 36 slides · Aug 12, 2026
- Investor Presentation (August 2026)
Investor deck · 57 slides · August 2026
- Investor Presentation (July 2026)
Investor deck · 59 slides · July 2026
- Investor Presentation (June 2026)
Investor deck · 59 slides · June 2026
- Investor Presentation (March 2026)
Investor deck · 22 slides · Mar 6, 2026
- Investor Presentation (March 2026)
Investor deck · 59 slides · March 2026
- Investor Presentation (February 2026)
Investor deck · 49 slides · Feb 13, 2026
- Investor Presentation (January 2026)
Investor deck · 37 slides · January 2026